Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 443 Show results per page	View Search Criteria \| Help With Results

Last Modified: 3/18/2008 First Published: 4/1/2001


1.		Phase II/III Randomized Study of Gemcitabine and Carboplatin Versus Methotrexate, Carboplatin, and Vinblastine in Previously Untreated Patients With Transitional Cell Cancer of the Urothelium Who are Ineligible for Cisplatin-Based Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Other				EORTC-GU-30986 NCT00014274

Last Modified: 12/5/2002 First Published: 6/1/2001


2.		Phase II/III Randomized Study of 2 Schedules of Gemcitabine With Best Supportive Care in Patients With Locally Advanced or Metastatic Poor Prognosis Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Other				CHNT-GEM EU-20062, NCT00022009

Last Modified: 6/25/2008 First Published: 6/23/2003


3.		Phase II/III Randomized Study of Gemcitabine Followed By Chemoradiotherapy With Gemcitabine Versus Gemcitabine Alone After Prior Curative Resection in Patients With Pancreatic Head Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Other				EORTC-40013 EORTC-22012, FFCD-0304, NCT00064207, EU-20540


4.		First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				CA183-002 NCT00389155


5.		Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				TG4010.09 NCT00415818

Last Modified: 3/1/2002


6.		Phase III Randomized Study of Marimastat (a Matrix Metalloproteinase Inhibitor) vs Gemcitabine as First-Line Therapy for Pancreatic Cancer (Summary Last Modified 03/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				BB-C03/IVB/128 NCI-V96-0908

Last Modified: 8/1/1998


7.		Phase III Randomized Study of Weekly Intravenous P-30 Protein plus Daily Oral Tamoxifen vs Weekly Intravenous Gemcitabine for Advanced Pancreatic Cancer (Summary Last Modified 08/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				21 and over				Pharmaceutical / Industry				ALFACELL-P30-303 NCI-V96-0938

Last Modified: 12/5/2006


8.		Phase III Randomized Study of Standard Chemotherapy with Paclitaxel/Cisplatin vs Gemcitabine/Cisplatin vs Docetaxel/Cisplatin vs Paclitaxel/Carboplatin in Metastatic non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				E-1594 E1594

Last Modified: 8/3/2007 First Published: 2/1/1998


9.		Phase III Randomized Study of Surgery With or Without Preoperative Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Any age				Other				MRC-LU22 EORTC-08012, EU-97016, ISRCTN25582437, NCT00003159

Last Modified: 7/21/2008 First Published: 4/1/1998


10.		Phase III Randomized Study of Adjuvant Fluorouracil-Based Chemoradiotherapy Preceded and Followed By Fluorouracil Versus Gemcitabine in Patients With Resected Adenocarcinoma of the Pancreas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				RTOG-9704 E-R9704, SWOG-R9704, NCT00003216, RTOG-97-04

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute